JP7678748B2 - 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 - Google Patents

血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 Download PDF

Info

Publication number
JP7678748B2
JP7678748B2 JP2021520923A JP2021520923A JP7678748B2 JP 7678748 B2 JP7678748 B2 JP 7678748B2 JP 2021520923 A JP2021520923 A JP 2021520923A JP 2021520923 A JP2021520923 A JP 2021520923A JP 7678748 B2 JP7678748 B2 JP 7678748B2
Authority
JP
Japan
Prior art keywords
agent
veds
pkc
erk
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021520923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504990A (ja
JP2022504990A5 (enExample
Inventor
ハリー シー． デイツ
ケイトリン ジェイ． ボーエン
ジアドロシク フアン フランシスコ カルデロン
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2022504990A publication Critical patent/JP2022504990A/ja
Publication of JP2022504990A5 publication Critical patent/JP2022504990A5/ja
Priority to JP2024031893A priority Critical patent/JP2024063161A/ja
Priority to JP2025076487A priority patent/JP2025118759A/ja
Application granted granted Critical
Publication of JP7678748B2 publication Critical patent/JP7678748B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021520923A 2018-10-16 2019-10-16 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法 Active JP7678748B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024031893A JP2024063161A (ja) 2018-10-16 2024-03-04 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法
JP2025076487A JP2025118759A (ja) 2018-10-16 2025-05-02 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862746524P 2018-10-16 2018-10-16
US62/746,524 2018-10-16
US201862747587P 2018-10-18 2018-10-18
US62/747,587 2018-10-18
US201962838049P 2019-04-24 2019-04-24
US62/838,049 2019-04-24
PCT/US2019/056616 WO2020081741A2 (en) 2018-10-16 2019-10-16 Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024031893A Division JP2024063161A (ja) 2018-10-16 2024-03-04 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法
JP2025076487A Division JP2025118759A (ja) 2018-10-16 2025-05-02 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022504990A JP2022504990A (ja) 2022-01-13
JP2022504990A5 JP2022504990A5 (enExample) 2022-09-20
JP7678748B2 true JP7678748B2 (ja) 2025-05-16

Family

ID=70284358

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021520923A Active JP7678748B2 (ja) 2018-10-16 2019-10-16 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法
JP2024031893A Pending JP2024063161A (ja) 2018-10-16 2024-03-04 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法
JP2025076487A Pending JP2025118759A (ja) 2018-10-16 2025-05-02 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024031893A Pending JP2024063161A (ja) 2018-10-16 2024-03-04 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法
JP2025076487A Pending JP2025118759A (ja) 2018-10-16 2025-05-02 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法

Country Status (16)

Country Link
US (2) US11938135B2 (enExample)
EP (2) EP4268822A3 (enExample)
JP (3) JP7678748B2 (enExample)
KR (1) KR20210094532A (enExample)
CN (2) CN121197400A (enExample)
AU (2) AU2019359872B2 (enExample)
BR (1) BR112021007237A2 (enExample)
CA (1) CA3116321A1 (enExample)
DK (1) DK3866799T3 (enExample)
ES (1) ES2973130T3 (enExample)
FI (1) FI3866799T3 (enExample)
IL (1) IL281623A (enExample)
MX (1) MX2021004387A (enExample)
PL (1) PL3866799T3 (enExample)
PT (1) PT3866799T (enExample)
WO (1) WO2020081741A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121197400A (zh) 2018-10-16 2025-12-26 约翰斯·霍普金斯大学 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
WO2021202643A1 (en) * 2020-03-31 2021-10-07 The Regents Of The University Of California Compositions and methods for treating dysregulated wound healing
EP4208203A4 (en) * 2020-09-04 2024-09-04 The Johns Hopkins University TREATMENT OF VASCULAR EHLERS-DANLOS SYNDROME AND ASSOCIATED SYNDROMES
WO2023150702A2 (en) * 2022-02-03 2023-08-10 The Johns Hopkins University Compositions and methods for treatment of connective tissue disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
DE102004019413A1 (de) 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
WO2013170147A1 (en) * 2012-05-11 2013-11-14 Yale University Compounds useful for promoting protein degradation and methods using same
AU2016232705C1 (en) * 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
BR112018008882A8 (pt) 2015-11-03 2019-02-26 Univ Texas método para tratar um distúrbio proliferativo e produto farmacêutico
WO2018160987A1 (en) 2017-03-02 2018-09-07 The Johns Hopkins University Map kinase pathway targets for the treatment of marfan syndrome
CN121197400A (zh) 2018-10-16 2025-12-26 约翰斯·霍普金斯大学 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cardiol Rev，2012年，Vol.20 No.1，p.4-7，doi: 10.1097/CRD.0b013e3182342316
eLife，2015年，Vol.4，Article.e08648 (p.1-18)，DOI: 10.7554/eLife.08648
医学のあゆみ，2018年01月20日，Vol.264 No.3，p.211-215
医学のあゆみ，2018年01月20日，Vol.264 No.3，p.227-233

Also Published As

Publication number Publication date
KR20210094532A (ko) 2021-07-29
CN121197400A (zh) 2025-12-26
AU2025200315A1 (en) 2025-02-13
JP2025118759A (ja) 2025-08-13
DK3866799T3 (da) 2024-02-05
PT3866799T (pt) 2024-03-06
WO2020081741A3 (en) 2020-05-22
BR112021007237A2 (pt) 2021-08-10
US20210386740A1 (en) 2021-12-16
IL281623A (en) 2021-05-31
EP3866799B1 (en) 2023-12-06
WO2020081741A2 (en) 2020-04-23
AU2019359872A1 (en) 2021-05-27
CN113194946A (zh) 2021-07-30
EP3866799A4 (en) 2022-07-27
CN113194946B (zh) 2025-10-14
MX2021004387A (es) 2021-08-19
FI3866799T3 (fi) 2024-02-29
ES2973130T3 (es) 2024-06-18
US20240408091A1 (en) 2024-12-12
EP3866799A2 (en) 2021-08-25
JP2024063161A (ja) 2024-05-10
EP4268822A3 (en) 2024-01-03
JP2022504990A (ja) 2022-01-13
PL3866799T3 (pl) 2024-04-29
AU2019359872B2 (en) 2024-10-17
CA3116321A1 (en) 2020-04-23
EP4268822A2 (en) 2023-11-01
US11938135B2 (en) 2024-03-26

Similar Documents

Publication Publication Date Title
RU2737496C2 (ru) Способы лечения рака
US20240408091A1 (en) Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders
RU2680714C2 (ru) Комбинированная терапия для лечения рака
WO2010014141A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US20250017921A1 (en) Pharmaceutical combination and tumor treatment
CN121335698A (zh) 用于治疗肝脏病症或心脏代谢疾病的包含THR-β激动剂和GLP-1R激动剂的组合
EP3849310B1 (en) Combination cancer therapies based on the mortalin targeting compound sheta2 and p53 reactivators or cdk4/6 inhibitors
Popescu et al. Multiselective RAS (ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML
US20060074109A1 (en) Use of inhibitors of 24-hydroxylase in the treatment of cancer
HK40094441A (en) Compositions for treating vascular ehlers danlos syndrome
HK40050331A (zh) 用於治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
EP2897644B1 (en) Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor and an aromatase inhibitor
Rinaldi FROM DISEASE GENE IDENTIFICATION TO THERAPEUTIC TARGETS IN NEUROMUSCULAR DISEASES

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220909

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250331

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250502

R150 Certificate of patent or registration of utility model

Ref document number: 7678748

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150